Adma Biologics Declines More Than Market Some Information for Investors
ADMA Stock | USD 21.83 0.01 0.05% |
About 60% of ADMA Biologics' investor base is looking to short. The analysis of the overall investor sentiment regarding ADMA Biologics suggests that many traders are alarmed. The current market sentiment, together with ADMA Biologics' historical and current headlines, can help investors time the market. In addition, many technical investors use ADMA Biologics stock news signals to limit their universe of possible portfolio assets.
ADMA |
Adma Biologics reachead 13.05 at the closing of the latest trading day, reflecting a -1.81 percent change compared to its last close.
Read at zacks.com
ADMA Biologics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards ADMA Biologics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
ADMA Biologics Fundamental Analysis
We analyze ADMA Biologics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ADMA Biologics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ADMA Biologics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Earnings Per Share
Earnings Per Share Comparative Analysis
ADMA Biologics is currently under evaluation in earnings per share category among its peers. Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
ADMA Biologics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with ADMA Biologics stock to make a market-neutral strategy. Peer analysis of ADMA Biologics could also be used in its relative valuation, which is a method of valuing ADMA Biologics by comparing valuation metrics with similar companies.
Peers
ADMA Biologics Related Equities
FATE | Fate Therapeutics | 18.28 | ||||
XFOR | X4 Pharmaceuticals | 11.43 | ||||
CRBU | Caribou Biosciences | 8.91 | ||||
MCRB | Seres Therapeutics | 4.55 | ||||
SANA | Sana Biotechnology | 4.08 | ||||
IBIO | Ibio | 3.54 | ||||
TFFP | Tff Pharmaceuticals | 3.33 | ||||
CDTX | Cidara Therapeutics | 3.11 | ||||
ETNB | 89bio | 2.70 | ||||
ANEB | Anebulo Pharmaceuticals | 2.14 | ||||
VXRT | Vaxart | 1.67 | ||||
PLRX | Pliant Therapeutics | 1.42 | ||||
STOK | Stoke Therapeutics | 1.19 | ||||
PLX | Protalix Biotherapeutics | 0.60 | ||||
AKBA | Akebia Ther | 0.49 | ||||
INMB | INmune Bio | 0.20 | ||||
BCRX | BioCryst Pharmaceuticals | 0.13 | ||||
RCUS | Arcus Biosciences | 0.06 | ||||
ATRA | Atara Biotherapeutics | 0.65 | ||||
ANTX | AN2 Therapeutics | 1.44 | ||||
MDGL | Madrigal Pharmaceuticals | 1.57 | ||||
ACLX | Arcellx | 2.08 | ||||
TNXP | Tonix Pharmaceuticals | 5.00 |
Complementary Tools for ADMA Stock analysis
When running ADMA Biologics' price analysis, check to measure ADMA Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ADMA Biologics is operating at the current time. Most of ADMA Biologics' value examination focuses on studying past and present price action to predict the probability of ADMA Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ADMA Biologics' price. Additionally, you may evaluate how the addition of ADMA Biologics to your portfolios can decrease your overall portfolio volatility.
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
FinTech Suite Use AI to screen and filter profitable investment opportunities |